Skip to main content

News Releases & Statements

News Releases & Statements

Join Us in Supporting Childhood Cancer Patients in Ukraine

As a healthcare organization dedicated to supporting all blood cancer patients, we at The Leukemia & Lymphoma Society (LLS) are horrified by the dire conditions facing childhood cancer patients in hospitals across Ukraine. Many are bunkering down with their families as medical staff deliver compromised treatments, face dwindling supplies, and evacuation becomes increasingly difficult.

Read More

FDA Approves New Drug for Patients with Rare Blood Cancer (Myelofibrosis)

Rye Brook, N.Y., February 28, 2022 – The Food and Drug Administration (FDA) recently approved a drug for the treatment of intermediate or high-risk primary or secondary myelofibrosis, the first specifically for patients with severely low platelet counts (thrombocytopenia). 

Read More

New Poll: Americans Believe It’s Time to Protect Consumers From Predatory Short-Term Health Plans

Washington, D.C., Jan. 25, 2022 —  An overwhelming majority of adults (79%) believes the government should regulate insurance products that exploit loopholes to discriminate against cancer patients and others with pre-existing conditions, according to a new national survey.

Read More
Burlington

Burlington Stores’ 20th Consecutive In-Store Fundraising Campaign Raises Nearly $3.4 Million for The Leukemia & Lymphoma Society

Funds will provide lifesaving treatments and support The LLS Children’s Initiative research pillar dedicated to pediatric cancer care innovation

Read More

FDA Approves First Drug for The Prevention of Acute Graft Versus Host Disease

Rye Brook, N.Y., December 15, 2021 – The Food and Drug Administration (FDA) recently approved abatacept (Orencia), in combination with certain immunosuppressants, for the prevention of acute graft versus host disease (aGVHD) in patients 2 years and older who underwent a stem cell transplant from an unrelated donor

Read More

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.  An LLS representative will respond as soon as possible.